减肥药板块股票走低 礼来(LLY.US)暴跌超5%

Core Viewpoint - The weight loss drug sector is under pressure due to regulatory delays, impacting major companies in the industry [1] Company Summaries - Eli Lilly (LLY.US) shares fell over 5% as the company's weight loss drug was placed on the FDA's review list, with a decision now postponed until April 10, 2026 [1] - Novo Nordisk (NVO.US) experienced a decline of over 4% in its stock price [1] - Pfizer (PFE.US) and Amgen (AMGN.US) both saw their shares drop by more than 1% [1]